Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation

José A Carrión ¹, Guillermo Fernández-Varo , Miquel Bruguera

⁰Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBERehd, Barcelona, Spain.

Gastroenterology +

|

September 30, 2009

View abstract on PubMed

Summary

Serum fibrosis markers accurately predict hepatitis C recurrence after liver transplantation. A novel algorithm using three markers (3-M-ALG) shows superior predictive performance for significant fibrosis and portal hypertension.

Area Of Science

Hepatology
Transplantation Immunology
Biomarker Discovery

Background

Hepatitis C virus (HCV) recurrence post-liver transplant can lead to significant fibrosis (F≥2) and portal hypertension (HVPG≥6 mm Hg).
Early identification of progressive recurrence is crucial for patient management.
This study investigated non-invasive serum fibrosis markers for predicting recurrence within the first year.

Purpose Of The Study

To evaluate the predictive capability of serum fibrosis markers for hepatitis C recurrence after liver transplantation.
To assess if a combination of markers can identify patients with significant fibrosis or portal hypertension early post-transplant.

Main Methods

Serum concentrations of hyaluronic acid, amino-terminal propeptide of type-III-procollagen, and tissue inhibitor of matrix metalloproteinase type-1 were measured in 133 HCV patients at 3, 6, and 12 months post-transplant.
Liver biopsies and HVPG measurements were performed at 1 year.
A novel 3-marker algorithm (3-M-ALG) was compared against established scores.

Main Results

At 1 year, 38% had significant fibrosis (F≥2) and 32% had HVPG≥6 mm Hg.
The 3-M-ALG demonstrated significantly higher predictive accuracy (AUC values up to 0.90) for fibrosis and HVPG compared to existing scores.
The 3-M-ALG at 12 months effectively identified patients at risk for decompensation or death.

Conclusions

Serum fibrosis markers, particularly the 3-M-ALG, offer a reliable, non-invasive method to predict hepatitis C recurrence post-liver transplant.
These markers can accurately differentiate between mild and progressive recurrence, aiding clinical decision-making.

Related Concept Videos